Harry & David recall nut-containing candy

Apr 16, 2007

The U.S. Food and Drug Administration announced the recall of approximately 2,000 boxes of candies distributed by the Harry & David Operations Corp.

The recalled candy might contain undeclared nuts, including peanuts, almonds, pecans, walnuts and cashews, thereby posing a health risk for people who are allergic to nuts.

Harry & David is recalling all lot codes of the products that were packaged in 6 oz. paperboard boxes with a folded over top. The candy, packaged with various striped color variations, includes: Dark Chocolate Clusters The Ultimate Walnut Cherry Caramel Indulgence candies in green and cream striped boxes; Dark Chocolate Clusters The Ultimate Peanut & Peanut Butter Indulgence in red and cream striped boxes; Dark Chocolate Clusters The Ultimate Pecan Cranberry Caramel Indulgence in dark red and cream striped boxes; Whole Almond Confection in brown and white striped boxes, and Whole Cashew Confection in dark red and cream striped boxes.

The candies were produced and packaged by a third party vendor and distributed nationwide through Harry and David Stores beginning in March.

Consumers can return the recalled candy for a full refund and can contact the Medford, Ore., company at 800-233-1101.

Copyright 2007 by United Press International

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

Someday, a way to 'see' nuclear, chemical threats

Apr 01, 2010

Ordinarily, the small square of plastic and glass has a reddish color. But when Drexel University graduate student Sameet Shriyan flicks a switch, applying a bit of electricity, suddenly the red fades and the material becomes ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Google+ boss leaving the company

The executive credited with bringing the Google+ social network to life is leaving the Internet colossus after playing a key role there for nearly eight years.